H. Pylori Infection Clinical Trial
Official title:
Comparison of Helicobacter Pylori Treatment Between Modified Quadruple Therapy and Tailored Eradication Based on the Presence of Clarithromycin Resistance
The rate of H. pylori resistance to antimicrobial agents including clarithromycin (CAM) has increased worldwide. Eradication failure using triple therapy is strongly associated with CAM-resistant H. pylori. The tailored therapy is defined as a targeted H. pylori eradication which emphasizes on predicting individual drug responses before treatment. Dual priming oligonucleotide (DPO)-based multiplex polymerase chain reaction (PCR) was developed to diagnose H. pylori infection and identify CAM resistance. The use of DPO-PCR has increased the tailored H. pylori eradication rate in Korea. If DPO-PCR testing is not available, a 14-day modified bismuth-containing quadruple regimen is recommended as a first-line H. pylori eradication. However, there is no comparison study between modified quadruple therapy and tailored eradication based on the presence of CAM resistance using DPO-PCR.
The investigators aim to evaluate the success rate, adverse drug events, and cost-effectiveness of modified quadruple therapy, compared with tailored eradication based on the presence of CAM resistance. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06045494 -
The Efficacy of Treatment for Helicobacter Pylori Infection in Preschooler by Yoghurt With LG21
|
N/A | |
Not yet recruiting |
NCT01449500 -
Supplementation With L. Reuteri in H. Pylori Infected Adults
|
N/A | |
Completed |
NCT01234389 -
Immediate Detection of Helicobacter Infection With a New Electrochemical System.
|
N/A | |
Not yet recruiting |
NCT05387005 -
Screening Strategy for Gastric Cancer Prevention
|
N/A | |
Not yet recruiting |
NCT02761005 -
Eradication of H. Pylori Therapy Individualized by the Mutation of 23S rRNA of H. Pylori
|
Phase 2 | |
Recruiting |
NCT03142620 -
Effect of Vitamin D on Drug Resistant Helicobacter Pylori (HP) Eradication Study
|
Phase 3 | |
Withdrawn |
NCT02090738 -
A Randomized, Open-label Study on Helicobacter Pylori Eradication With Standard Triple Regimen Plus Acetazolamide
|
Phase 2 | |
Recruiting |
NCT01335334 -
H. Pylori Eradication Using Pyklear in Adults in El Paso, Texas: a Pilot Study
|
Phase 4 | |
Recruiting |
NCT05544396 -
Study on the Probiotics Regulating miRNA in H. Pylori-induced Wnt/β-catenin Gastric Carcinogenesis.
|
N/A | |
Recruiting |
NCT04713670 -
Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection
|
Phase 4 | |
Recruiting |
NCT06045832 -
Oral Helicobacter Pylori Eradication
|
N/A | |
Completed |
NCT05453994 -
Bismuth for PCAB-based H. Pylori Eradication
|
||
Recruiting |
NCT02328131 -
European Registry on the Management of Helicobacter Pylori Infection
|
||
Completed |
NCT00197457 -
Pepsinogens as the Early Marker of H. Pylori Eradication
|
Phase 2 | |
Not yet recruiting |
NCT06412640 -
Optimization of Keverprazan-amoxicilli Dual Therapy for Helicobacter Pylori
|
Phase 4 | |
Completed |
NCT04036838 -
ARJ C13 Urea Breath Test System
|
Phase 2 | |
Completed |
NCT06050824 -
A Comparative Study Between Concomitant Versus Load Therapy in Eradication of Helicobacter Pylori Infection
|
Phase 4 | |
Completed |
NCT02767479 -
Comparison of Rabeprazole and Esomperazole for the Eradication of H. Pylori
|
Phase 3 | |
Completed |
NCT01505127 -
Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori
|
Phase 3 | |
Recruiting |
NCT05176821 -
Eradication Efficacy and Safety of Two Rescue Treatments for Helicobacter Pylori Infection
|
N/A |